Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-01-09
2007-01-09
Campell, Bruce (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
10988628
ABSTRACT:
The invention described herein relates to the use of human interleukin-6 antagonists, totally incapable of binding to gp 130, as specific inhibitors of the enzyme aromatase, useful for the treatment of hormone-dependent tumours, and particularly tumours of the breast.
REFERENCES:
patent: WO 96/34104 (1996-10-01), None
patent: WO-96/34104 (1996-10-01), None
patent: WO 96/44104 (1996-10-01), None
patent: WO 98/13383 (1998-04-01), None
patent: WO 98/15283 (1998-04-01), None
On-Line Medical Dictionary (http://cancerweb.ncl.ac.uk/cgi-bin/omd?query=aromatase; Dec. 12, 1998).
Henry et al., “Molecular Markers of Malignant Neoplasms”, in Clinical Diagnosis and Management by Laboratory Methods, 1991, pp. 302-303.
Ehlers et al. “Combining two mutations of human interleukin-6 that affect gp 130 activation results in a potent interleukin-6 receptor antagonist on human myeloma cells” J. Biol. Chem. 270:8158-8163 (1995).
Paonessa et al. “Two distinct and independent sites on IL-6 trigger gp130 dimer formation and signalling” EMBO J. 14:1942-1951 (1995).
Reed et al. “Breast cancer and the role of cytokines in regulating estrogen synthesis: An emerging hypothesis” Endocr. Rev. 18:701-715 (1997).
Audet Maury
Campell Bruce
Nixon & Vanderhye P.C.
Sigma Tau Industrie Farmaceutiche Riunite S.p.A.
LandOfFree
Use of interleukin-6 antagonists for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of interleukin-6 antagonists for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of interleukin-6 antagonists for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3804552